Log In
BCIQ
Print this Print this
 

Montelukast/Levocetirizine (HCP1102)

  Manage Alerts
Collapse Summary General Information
Company Hanmi Pharmaceutical Co. Ltd.
DescriptionFixed dose combination of Montelukast / Levocetirizine
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase III
Standard IndicationRhinitis
Indication DetailsTreat perennial allergic rhinitis (PAR)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today